401 related articles for article (PubMed ID: 15337666)
1. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.
Leslie DL; Rosenheck RA
Am J Psychiatry; 2004 Sep; 161(9):1709-11. PubMed ID: 15337666
[TBL] [Abstract][Full Text] [Related]
2. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia.
Ollendorf DA; Joyce AT; Rucker M
MedGenMed; 2004 Jan; 6(1):5. PubMed ID: 15208518
[TBL] [Abstract][Full Text] [Related]
3. Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population.
Miller EA; Leslie DL; Rosenheck RA
J Nerv Ment Dis; 2005 Jun; 193(6):387-95. PubMed ID: 15920379
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
5. Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States.
Feldman PD; Hay LK; Deberdt W; Kennedy JS; Hutchins DS; Hay DP; Hardy TA; Hoffmann VP; Hornbuckle K; Breier A
J Am Med Dir Assoc; 2004; 5(1):38-46. PubMed ID: 14706127
[TBL] [Abstract][Full Text] [Related]
6. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study.
Østbye T; Curtis LH; Masselink LE; Hutchison S; Wright A; Dans PE; Schulman KA; Krishnan RR
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):407-15. PubMed ID: 15372671
[TBL] [Abstract][Full Text] [Related]
7. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia.
Lambert BL; Cunningham FE; Miller DR; Dalack GW; Hur K
Am J Epidemiol; 2006 Oct; 164(7):672-81. PubMed ID: 16943266
[TBL] [Abstract][Full Text] [Related]
8. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
Sernyak MJ; Leslie DL; Alarcon RD; Losonczy MF; Rosenheck R
Am J Psychiatry; 2002 Apr; 159(4):561-6. PubMed ID: 11925293
[TBL] [Abstract][Full Text] [Related]
9. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients.
Citrome L; Jaffe A; Levine J; Allingham B; Robinson J
Psychiatr Serv; 2004 Sep; 55(9):1006-13. PubMed ID: 15345760
[TBL] [Abstract][Full Text] [Related]
10. A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine.
Sumiyoshi T; Roy A; Anil AE; Jayathilake K; Ertugrul A; Meltzer HY
J Clin Psychopharmacol; 2004 Jun; 24(3):345-8. PubMed ID: 15118492
[No Abstract] [Full Text] [Related]
11. Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need.
Cohen D; Correll CU
J Clin Psychiatry; 2009 May; 70(5):765-6. PubMed ID: 19552870
[No Abstract] [Full Text] [Related]
12. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature.
Cohen D
Pharmacopsychiatry; 2004 Jan; 37(1):1-11. PubMed ID: 14750042
[TBL] [Abstract][Full Text] [Related]
13. Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study.
Chatterjee S; Chen H; Johnson ML; Aparasu RR
Am J Geriatr Pharmacother; 2012 Apr; 10(2):83-94. PubMed ID: 22306198
[TBL] [Abstract][Full Text] [Related]
14. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
van Winkel R; De Hert M; Wampers M; Van Eyck D; Hanssens L; Scheen A; Peuskens J
J Clin Psychiatry; 2008 Mar; 69(3):472-9. PubMed ID: 18348593
[TBL] [Abstract][Full Text] [Related]
15. [The appearance of metabolic syndrome in treatment with atypical antipsychotics].
Mosolov SN; Kabanov SO
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):62-9. PubMed ID: 14681970
[No Abstract] [Full Text] [Related]
16. Two new atypical antipsychotics: advantages and disadvantages.
Lemon MD
S D J Med; 1998 Aug; 51(8):285-6. PubMed ID: 9724957
[No Abstract] [Full Text] [Related]
17. The value of atypical antipsychotics in the treatment of schizophrenia.
Jessen LM
Manag Care; 2002 Jul; 11(7 Suppl):8-12; discussion 12-3. PubMed ID: 12181875
[No Abstract] [Full Text] [Related]
18. New-onset diabetes and ketoacidosis with atypical antipsychotics.
Wilson DR; D'Souza L; Sarkar N; Newton M; Hammond C
Schizophr Res; 2003 Jan; 59(1):1-6. PubMed ID: 12413635
[TBL] [Abstract][Full Text] [Related]
19. [Effect of side-effects and complications caused by atypical neuroleptics on the effectiveness of therapy in patients with schizophrenia].
Danilov DS
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(3):48-55. PubMed ID: 20517226
[TBL] [Abstract][Full Text] [Related]
20. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics.
Henderson DC; Cagliero E; Copeland PM; Louie PM; Borba CP; Fan X; Freudenreich O; Goff DC
J Clin Psychiatry; 2007 Apr; 68(4):533-41. PubMed ID: 17474808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]